ALIREZA HAZRATI: Open Payments
NPI 1942692587 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,014 in 60 payments from 18 companies in 2025. Trend: 2023 $913 · 2024 $1,410 · 2025 $3,014
Food & beverage: $3,014
| Company | Payments | Amount |
|---|---|---|
| AOP Health US, LLC | 2 | $1,842 |
| Abbott Laboratories | 15 | $217 |
| Novo Nordisk Inc | 5 | $135 |
| Novartis Pharmaceuticals Corporation | 6 | $133 |
| Merck Sharp & Dohme LLC | 5 | $121 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $95 |
| E.R. Squibb & Sons, L.L.C. | 5 | $88 |
| Boston Scientific Corporation | 4 | $77 |
| PFIZER INC. | 4 | $68 |
| Kestra Medical Technology Services, Inc. | 1 | $59 |
Products named: Rapiblyk, Wegovy, LEQVIO, JARDIANCE, VERQUVO, CAMZYOS, ELIQUIS, Assure WCD.
Industry payments across MD — which companies pay providers there.
